Study of SRF617 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
A Phase 1, first-in-human, SRF617 monotherapy and combination therapy, dose escalation,
safety, and tumor biopsy expansion study of SRF617, an antibody that inhibits CD39 activity,
in patients with advanced solid tumors. Inhibition of CD39 activity may improve the ability
to mount an immune response against tumor cells.